Meeting
2022 ASCO Annual Meeting
SPECT-defined, active bone marrow–sparing, volumetric-modulated arc therapy reduces the incidence of acute hematologic toxicity in patients with locally advanced cervical cancer who receive chemoradiotherapy.
Authors
Shan Bing Wang
Department of Oncology,the Second People Hospital of YiBin City, Yibin, China
Shan Bing Wang , JiaPei Liu , Yuming Jia , Kaijian Lei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
ChiCTR-IOR-16010214
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5527)
DOI
10.1200/JCO.2022.40.16_suppl.5527
Abstract #
5527
Poster Bd #
406
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Active bone marrow-sparing to reduce the incidence of grade 3+ acute hematologic toxicity in patients with locally advanced cervical cancer who receive chemoradiotherapy: A single-center prospective randomized controlled trial.
First Author: ShanBing Wang
Poster
2022 ASCO Annual Meeting
Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial.
First Author: Manuel Rodrigues
Poster
2017 ASCO Annual Meeting
A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer.
First Author: Linda R. Duska
Poster
2024 ASCO Annual Meeting
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.
First Author: Manabu Muto